( WellferonB, Glaxo-Wellcome), natural leukocyte (CilferonB, Janssen-Cilag) and raIFN (Intron-AB, Schering-Plough), 3 It is well known that prolonged administration of recombinant alpha interferon (raIFN ) in several viral and malignant dis-MU intramuscularly, daily or on alternate days depending on the clinical outcome, evaluated as in our former paper (4). eases can be followed by loss of clinical activity of the drug. In the majority of these cases, the occurrence of insensitiveness Etretinate, 50 mg/day orally, is routinely coupled. After more than 3 years of experience, we have observed no loss of clinical to raIFN could depend on the synthesis of biologically active raIFN-neutralizing endogenous antibodies (1), although some effectiveness of IFNs in 7 of the 8 patients we have been treating. argue that a cause-and-effect relation between these facts has not been proven (2). Recently, others have pointed out that Formerly we predicted that alternative use of various kinds of IFNs could prove effective in treating lymphoproliferative even non-neutralizing IFN antibodies could be relevant in affecting alpha interferon efficacy (3). We started using alterndiseases of the skin selectively (4). On the ground of our satisfying pilot results we confirm our belief, and we encourage ate treatment with different interferons (IFNs) in 1994, when we observed our first case of resistance to raIFN in connection other groups to try such alternating protocols on extended series of CTCL patients in order to lay the groundwork for with the treatment of cutaneous T-cell lymphoma (CTCL). These are our pilot reports.
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controlled studies. Incidentally, we must unfortunately recognize that public health service officials are indifferent to, or even mistrustful of empirical therapeutic attempts, which are CASE REPORTS needed in the specialized management of rare conditions for less frequently (6). Moreover, it had already been stated that 7. Dianzani F, Antonelli P, Amicucci P. Low incidence of neutralizing in many instances therapeutic efficacy could be re-established antibody formation to interferon-alfa 2b in human recipients.
by resuming treatment with natural alpha-IFN (7). These 
